- Home
- RLMD vs BCDA Comparison
RLMD vs BCDA Comparison
Compare RLMD & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- BCDA
- Stock Information
- Founded
- RLMD 2004
- BCDA N/A
- Country
- RLMD United States
- BCDA United States
- Employees
- RLMD N/A
- BCDA N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- BCDA Health Care
- Exchange
- RLMD Nasdaq
- BCDA Nasdaq
- Market Cap
- RLMD 11.5M
- BCDA 9.4M
- IPO Year
- RLMD N/A
- BCDA N/A
- Fundamental
- Price
- RLMD $0.30
- BCDA $2.27
- Analyst Decision
- RLMD Hold
- BCDA Strong Buy
- Analyst Count
- RLMD 4
- BCDA 1
- Target Price
- RLMD $4.25
- BCDA $25.00
- AVG Volume (30 Days)
- RLMD 382.7K
- BCDA 94.4K
- Earning Date
- RLMD 03-27-2025
- BCDA 03-26-2025
- Dividend Yield
- RLMD N/A
- BCDA N/A
- EPS Growth
- RLMD N/A
- BCDA N/A
- EPS
- RLMD N/A
- BCDA N/A
- Revenue
- RLMD N/A
- BCDA $58,000.00
- Revenue This Year
- RLMD N/A
- BCDA N/A
- Revenue Next Year
- RLMD N/A
- BCDA N/A
- P/E Ratio
- RLMD N/A
- BCDA N/A
- Revenue Growth
- RLMD N/A
- BCDA N/A
- 52 Week Low
- RLMD $0.24
- BCDA $1.63
- 52 Week High
- RLMD $5.09
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- RLMD 50.05
- BCDA 42.76
- Support Level
- RLMD $0.26
- BCDA $2.45
- Resistance Level
- RLMD $0.32
- BCDA $2.95
- Average True Range (ATR)
- RLMD 0.02
- BCDA 0.23
- MACD
- RLMD 0.00
- BCDA -0.04
- Stochastic Oscillator
- RLMD 67.34
- BCDA 20.92
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).